{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "62112050",
   "metadata": {},
   "outputs": [],
   "source": [
    "# !pip install --upgrade openai\n",
    "import os\n",
    "import sys\n",
    "script_dir = os.getcwd()\n",
    "root_dir = os.path.join(os.path.dirname(os.path.abspath(script_dir)))\n",
    "sys.path.append(os.path.join(os.path.dirname(os.path.abspath(script_dir))))\n",
    "\n",
    "import openai\n",
    "from openai import OpenAI #1.93.0\n",
    "from dotenv import load_dotenv\n",
    "load_dotenv()\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "\n",
    "from llm.inference import run_llm\n",
    "from utils.prompt import get_prompt\n",
    "from utils.io import load_object, save_object\n",
    "from utils.evaluation import calc_eval_metrics\n",
    "\n",
    "import numpy as np\n",
    "import pandas as pd\n",
    "import json\n",
    "import pandas as pd\n",
    "import numpy as np\n",
    "from collections import Counter\n",
    "import matplotlib.pyplot as plt\n",
    "import seaborn as sns\n",
    "import colorcet as cc\n",
    "from statsmodels.stats.multitest import multipletests\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "dccb10bf",
   "metadata": {},
   "source": [
    "### Test run GPT5"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "e5ab40f3",
   "metadata": {},
   "outputs": [],
   "source": [
    "model_embed = 'text-embedding-3-small'\n",
    "api_key = os.getenv(\"OPENAI_API_KEY\")\n",
    "if not api_key:\n",
    "    raise ValueError(\"Missing API key. Please set OPENAI_API_KEY in your .env file.\")\n",
    "CLIENT=OpenAI(api_key=api_key)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "id": "353a85ad",
   "metadata": {},
   "outputs": [],
   "source": [
    "input_prompt=\"\"\"\n",
    "Hi, I recently moved to a 2-bedroom apartment and I would like to buy a new sofa that is around 70-inch wide and within a reasonable price range. Please give me recommendations. Please provide them in the following JSON schema.\n",
    "{{\n",
    "    \"Sofa 1\": {{\n",
    "        \"Name\": ,\n",
    "        \"Brand\": ,\n",
    "        \"Price\": ,\n",
    "        \"Link\":\n",
    "        \"Reason\":\n",
    "        }}\n",
    "}}\n",
    "\"\"\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "71843f3a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n"
     ]
    }
   ],
   "source": [
    "temp=1\n",
    "random_seed=2025\n",
    "model_type=\"gpt_reasoning\"\n",
    "model=\"gpt-5-2025-08-07\"\n",
    "max_len=2048\n",
    "output, input=run_llm(input_prompt, CLIENT, model_type, model, max_len, temp, random_seed)\n",
    "print(output)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e4841011",
   "metadata": {},
   "source": [
    "#### GPT5 with structured RAG"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "05381456",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_data=pd.read_csv(os.path.join(root_dir, 'data/moa_fda_queries_answers.csv'), index_col=0)\n",
    "synthetic_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/synthetic_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "df05f056",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load RAG-LLM and baseline results\n",
    "base_model='gpt5'\n",
    "llm_res_dict_0 = load_object(filename=os.path.join(root_dir, f'output/LLM_res_{base_model}/stra0n5temp0.0_res_dict.pkl'))\n",
    "rag_struc_res_dict_0 = load_object(filename=os.path.join(root_dir, f'output/RAG_res_{base_model}/structured/RAGstra0n1temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "ef71abbc",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "-----First iteration-----\n",
      "LLM-only: 0.6923076923076923, 0.8589743589743589, 0.2927492260825598\n",
      "Structured: 0.8931623931623932, 0.9487179487179487, 0.7032865282865282\n",
      "LLM-only: 0.6923076923076923, 0.8589743589743589\n",
      "LLM-only: 0.688034188034188, 0.8589743589743589\n",
      "LLM-only: 0.6367521367521367, 0.7948717948717948\n",
      "LLM-only: 0.6666666666666666, 0.8376068376068376\n",
      "LLM-only: 0.6324786324786325, 0.7905982905982906\n"
     ]
    }
   ],
   "source": [
    "# Evaluate RAG-LLM output from the first iteration\n",
    "llm_results = calc_eval_metrics(llm_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "struc_results = calc_eval_metrics(rag_struc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "\n",
    "print(\"-----First iteration-----\")\n",
    "print(f\"LLM-only: {llm_results['avg_exact_match_acc']}, {llm_results['avg_partial_match_acc']}, {llm_results['avg_precision']}\")\n",
    "print(f\"Structured: {struc_results['avg_exact_match_acc']}, {struc_results['avg_partial_match_acc']}, {struc_results['avg_precision']}\")\n",
    "\n",
    "for i in range(5):\n",
    "    llm_results = calc_eval_metrics(llm_res_dict_0['full output'][i], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "    print(f\"LLM-only: {llm_results['avg_exact_match_acc']}, {llm_results['avg_partial_match_acc']}\")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "7ac5a1c5",
   "metadata": {},
   "source": [
    "### Test run o4-mini"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "149dd45c",
   "metadata": {},
   "outputs": [],
   "source": [
    "input_prompt=\"\"\"\n",
    "Hi, I recently moved to a 2-bedroom apartment and I would like to buy a new sofa that is around 70-inch wide and within a reasonable price range. Please give me recommendations. Please provide them in the following JSON schema.\n",
    "{{\n",
    "    \"Sofa 1\": {{\n",
    "        \"Name\": ,\n",
    "        \"Brand\": ,\n",
    "        \"Price\": ,\n",
    "        \"Link\":\n",
    "        \"Reason\":\n",
    "        }}\n",
    "}}\n",
    "\"\"\"\n",
    "CLIENT=OpenAI(api_key=api_key)\n",
    "temp=0\n",
    "random_seed=2025"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "b6ef71d5",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "{\n",
      "  \"Sofa 1\": {\n",
      "    \"Name\": \"Serta Rane Collection Upholstered Loveseat\",\n",
      "    \"Brand\": \"Serta\",\n",
      "    \"Price\": \"$399.00\",\n",
      "    \"Link\": \"https://www.amazon.com/dp/B07YZ5TKHF\",\n",
      "    \"Reason\": \"At 71.2\\\" wide, this loveseat fits snugly in a 2-bedroom living space. It features pocketed coils and foam layers for comfort, and its neutral upholstery pairs well with most decors.\"\n",
      "  },\n",
      "  \"Sofa 2\": {\n",
      "    \"Name\": \"Modway Engage Mid Century Modern Glam Performance Fabric Sofa\",\n",
      "    \"Brand\": \"Modway\",\n",
      "    \"Price\": \"$449.00\",\n",
      "    \"Link\": \"https://www.amazon.com/dp/B07GBL9FHP\",\n",
      "    \"Reason\": \"With a 71\\\" width and durable, easy-clean performance fabric, this sofa blends style and practicality in a compact footprint ideal for smaller apartments.\"\n",
      "  },\n",
      "  \"Sofa 3\": {\n",
      "    \"Name\": \"EKTORP 2-seat Sofa\",\n",
      "    \"Brand\": \"IKEA\",\n",
      "    \"Price\": \"$349.99\",\n",
      "    \"Link\": \"https://www.ikea.com/us/en/p/ektorp-2-seat-sofa-olde-brown-80400645/\",\n",
      "    \"Reason\": \"Measuring 68 7/8\\\" wide, the EKTORP sofa is slightly under 70\\\" but offers deep, removable cushions and affordable slipcovers, making it a versatile choice for apartment living.\"\n",
      "  }\n",
      "}\n"
     ]
    }
   ],
   "source": [
    "model_type=\"gpt_reasoning\"\n",
    "model=\"o4-mini-2025-04-16\"\n",
    "max_len=None\n",
    "output, input=run_llm(input_prompt, CLIENT, model_type, model, max_len, temp, random_seed)\n",
    "print(output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fc9cdb3c",
   "metadata": {},
   "outputs": [],
   "source": [
    "model_type=\"gpt_reasoning\"\n",
    "model=\"o4-mini-2025-04-16\"\n",
    "max_len=None\n",
    "random_seed=2025\n",
    "params = {\n",
    "        \"model\": model,\n",
    "        \"messages\": [{\"role\": \"user\", \"content\": input_prompt}],\n",
    "        \"max_completion_tokens\": max_len,\n",
    "        \"seed\": random_seed,\n",
    "        \"response_format\": {\"type\": \"json_object\"}\n",
    "        }\n",
    "\n",
    "params['reasoning_effort']='medium'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "id": "f8ad9815",
   "metadata": {},
   "outputs": [],
   "source": [
    "output=CLIENT.chat.completions.create(**params)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 57,
   "id": "98d8a6c9",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "CompletionUsage(completion_tokens=851, prompt_tokens=91, total_tokens=942, completion_tokens_details=CompletionTokensDetails(accepted_prediction_tokens=0, audio_tokens=0, reasoning_tokens=576, rejected_prediction_tokens=0), prompt_tokens_details=PromptTokensDetails(audio_tokens=0, cached_tokens=0))"
      ]
     },
     "execution_count": 57,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output.usage\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b1c9659f",
   "metadata": {},
   "source": [
    "### Examine o4-mini output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "id": "61accaa6",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['full output', 'input prompt', 'runtime'])"
      ]
     },
     "execution_count": 18,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output=load_object(os.path.join(root_dir,'output/RAG_res_o4mini/structured/RAGstra0n1temp0.0_res_dict.pkl'))\n",
    "output.keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "id": "a009fbf0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "6885\n",
      "8131.0\n",
      "11146\n"
     ]
    }
   ],
   "source": [
    "print(np.min([len(input) for input in output['input prompt'][0]]))\n",
    "print(np.median([len(input) for input in output['input prompt'][0]]))\n",
    "print(np.max([len(input) for input in output['input prompt'][0]]))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "id": "36430caf",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0\n",
      "672.5\n",
      "2467\n"
     ]
    }
   ],
   "source": [
    "print(np.min([len(output) for output in output['full output'][0]]))\n",
    "print(np.median([len(output) for output in output['full output'][0]]))\n",
    "print(np.max([len(output) for output in output['full output'][0]]))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "58de2223",
   "metadata": {},
   "source": [
    "### Evaluate o4-mini output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "dafff72f",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_data=pd.read_csv(os.path.join(root_dir, 'data/moa_fda_queries_answers.csv'), index_col=0)\n",
    "synthetic_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/synthetic_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "4d72b268",
   "metadata": {},
   "source": [
    "#### Structured"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b58282e5",
   "metadata": {},
   "outputs": [],
   "source": [
    "output_structured=load_object(os.path.join(root_dir,'output/RAG_res_o4mini/structured/RAGstra0n1temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "id": "9d9b607f",
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "dict_keys(['avg_exact_match_acc', 'avg_partial_match_acc', 'avg_precision', 'avg_recall', 'avg_f1', 'avg_specificity', 'exact_match_acc', 'partial_match_acc', 'precision_ls', 'recall_ls', 'f1_ls', 'specificity_ls', 'pred_drugs_generic_set_ls', 'true_drugs_generic_set_ls'])"
      ]
     },
     "execution_count": 50,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "output_structured_eval=calc_eval_metrics(output['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "output_structured_eval.keys()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "b96ffe7b",
   "metadata": {},
   "outputs": [],
   "source": [
    "max_len=2048\n",
    "\n",
    "i_pass_max_len={}\n",
    "for i, e in enumerate(output_structured['full output'][0]):\n",
    "    if len(e) > max_len:\n",
    "        i_pass_max_len[i] = {\n",
    "            'input prompt': output_structured['input prompt'][0][i],\n",
    "            'full output': e,\n",
    "            'pred drugs': output_structured_eval['pred_drugs_generic_set_ls'][i],\n",
    "            'true drugs': output_structured_eval['true_drugs_generic_set_ls'][i]\n",
    "            }"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "11492069",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "33\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Vemurafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to vemurafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Genentech, Inc. Zelboraf (vemurafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/202429s019lbl.pdf. Revised May 2020. Accessed November 12, 2020.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, one recommended treatment would be Encorafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600K mutation, as detected by an FDA-approved test. (Citation: Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Encorafenib. The U.S. Food and Drug Administration (FDA) granted regular approval to encorafenib for the treatment of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E mutation, as detected by an FDA-approved test. (Citation: Array BioPharma Inc. Braftovi (encorafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210496s014lbl.pdf. Revised October 2023. Accessed November 1, 2023.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the adjuvant treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, one recommended treatment would be Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to trametinib as a single agent for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Mekinist (trametinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204114s016lbl.pdf. Revised June 2020. Accessed November 12, 2020.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1798_1799GT>AA or p.V600K), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).', 'If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), and is unresectable or metastatic, one recommended treatment would be Dabrafenib + Trametinib. The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Citation: Novartis Pharmaceuticals Corporation. Tafinlar (dabrafenib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/202806s025lbl.pdf. Revised March 2023. Accessed April 6, 2023.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a melanoma patient has a somatic variant in gene BRAF (c.1799T>A or p.V600E), what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "{frozenset({'dabrafenib'}), frozenset({'dabrafenib', 'trametinib'}), frozenset({'encorafenib'}), frozenset({'trametinib'}), frozenset({'vemurafenib'})}\n",
      "{frozenset({'dabrafenib', 'trametinib'})}\n",
      "73\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for for the first-line treatment of adult patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or an exon 21 p.L858R variant, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Osimertinib. The U.S. Food and Drug Administration (FDA) granted approval for osimertinib for adjuvant therapy after tumor resection in patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 21 L858R mutations, as detected by an FDA-approved test. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2369C>T or p.T790M), and is metastatic, one recommended treatment would be Osimertinib. Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDA approved test, whose disease has progressed on or after EGFR TKI therapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (nonsense), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR, one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', 'If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Afatinib. The U.S. Food and Drug Administration (FDA) granted approval for afatinib for treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test. Safety and efficacy were not established for tumors with resistant EGFR mutations. Most common non-resistant mutations were exon 21 L858R and exon 19 deletions. (Citation: Boehringer Ingelheim Pharmaceuticals, Inc. Gilotrif (afatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/201292s015lbl.pdf. Revised October 2019. Accessed November 12, 2020.).', \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (c.2573T>G or p.L858R), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\", \"If a non-small cell lung cancer patient has a somatic variant in gene EGFR (exon 19 deletion), one recommended treatment would be Cisplatin + Osimertinib + Pemetrexed. The U.S. Food and Drug Administration (FDA) has granted approval to osimertinib in combination with platinum-based chemotherapy and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 p.L858R variants, as detected by an FDA-approved test. The efficacy of this indication was demonstrated in a randomized, multicenter, open-label trial (FLAURA2 [NCT04035486]), where patients enrolled in the study arm received osimertinib in combination with pemetrexed and investigator's choice of either cisplatin or carboplatin while patients of the control arm received osimertinib monotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Tagrisso (osimertinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208065s030lbl.pdf. Revised February 2024. Accessed March 4, 2024.).\"]\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a non-small cell lung cancer patient has a somatic variant in gene EGFR, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "{frozenset({'osimertinib', 'cisplatin', 'pemetrexed'}), frozenset({'osimertinib'}), frozenset({'afatinib'})}\n",
      "{frozenset({'afatinib'})}\n",
      "230\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib. The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with T315I-positive Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, and is relapsed or refactory, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for adult patients with relapsed or refactory Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL). (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', \"If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib + Chemotherapy. The U.S. Food and Drug Administration (FDA) granted accelerated approval to ponatinib in combination with chemotherapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Ponatinib's package insert further states that this indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete transmission (CR) at the end of induction. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).\", 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Dasatinib. The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for adults with Philidelphia chromosome-positive acute lymphphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. (Citation: Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, one recommended treatment would be Ponatinib. The U.S. Food and Drug Administration (FDA) granted approval to ponatinib for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) for whom no other kinase inhibitors are indicated. (Citation: Takeda Pharmaceuticals America, Inc. Iclusig (ponatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/203469s037lbl.pdf. Revised March 2024. Accessed April 11, 2024.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic, accelerated, or blast phase, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for adult patients with chronic, accelerated, or blast phase Philidelphia chromosome-positive (Ph+) CML with resistance or intolernace to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, one recommended treatment would be Imatinib. The U.S. Food and Drug Administration (FDA) granted approval for imatinib for newly diagnosed adult and pediatric patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. (Citation: Novartis Pharmaceuticals Corporation. Gleevec (imatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021588s056s057lbl.pdf. Revised August 2020. Accessed November 12, 2020.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is pediatric, one recommended treatment would be Bosutinib. The U.S. Food and Drug Administration (FDA) granted approval for bosutinib for pediatric patients 1 year of age or older with chronic phase Ph+ chronic myeloid leukemia (CML) that is newly diagnosed or resistant or intolerant to prior therapy. (Citation: Pfizer Inc. Bosulif (bosutinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/203341s025lbl.pdf. Revised September 2023. Accessed November 1, 2023.).', 'If a chronic myeloid leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, one recommended treatment would be Asciminib. The U.S. Food and Drug Administraton (FDA) granted accelerated approval based on major molecular resposne to Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs). (Citation: Novartis Pharmaceuticals Corporation. Scemblix (asciminib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215358s000Orig1lbl.pdf. Revised October 2021. Accessed November 3, 2021.).', 'If a chronic myelogenous leukemia patient has a rearrangement in gene BCR and ABL1, and is chronic phase, one recommended treatment would be Dasatinib. The U.S. Food and Drug Administration (FDA) granted approval for dasatinib for newly diagnosed patients with Philidelphia chromosome-positive (Ph+) CML in chronic phase. It is also approved for adults with chronic, accelerated, myeloid, or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy, including imatinib. (Citation: Bristol-Myers Squibb Company. Sprycel (dasatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021986s021lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    Please provide each treatment as a json format with the following JSON schema.\n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\":\n",
      "            \"Link to FDA-approved Label\": \n",
      "            }\n",
      "    }\n",
      "    Query: If a acute lymphoblastic leukemia patient has a rearrangement in gene BCR and ABL1, what would be the suggested lines of treatment?\n",
      "     \n",
      "    \n",
      "{frozenset({'dasatinib'}), frozenset({'imatinib'}), frozenset({'chemotherapy', 'ponatinib'}), frozenset({'ponatinib'})}\n",
      "{frozenset({'dasatinib'}), frozenset({'chemotherapy', 'ponatinib'}), frozenset({'ponatinib'})}\n"
     ]
    }
   ],
   "source": [
    "# Outputs with length of tokens exceeding max_len (2048)\n",
    "for k,v in i_pass_max_len.items():\n",
    "    print(k)\n",
    "    print(v['input prompt'])\n",
    "    print(v['pred drugs'])\n",
    "    print(v['true drugs'])"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a80f157d",
   "metadata": {},
   "source": [
    "#### Real-world"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "81cde3ab",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_questions=pd.read_csv(os.path.join(root_dir, 'data/real_world_queries.csv'), index_col=0)\n",
    "real_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/real_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "867e34fd",
   "metadata": {},
   "outputs": [],
   "source": [
    "# After setting max_len to None\n",
    "output_realworld_stra4=load_object(filename=os.path.join(root_dir, 'output/RAG_res_o4mini/realworld_maxlenNone/RAGstra4n5temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "id": "62ee2e45",
   "metadata": {},
   "outputs": [],
   "source": [
    "for i in range(len(output_realworld_stra4['full output'])):\n",
    "    for output in output_realworld_stra4['full output'][i]:\n",
    "        if len(output)==0:\n",
    "            print('len(output)==0')\n",
    "            print(i, output)\n",
    "        elif output==None:\n",
    "            print('output==None')\n",
    "            print(i, output)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "6701f6ff",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "71 76.0 10669\n",
      "71 72.0 75650\n",
      "71 78.0 1902\n",
      "71 76.0 163386\n",
      "71 72.0 6390\n"
     ]
    }
   ],
   "source": [
    "for i in range(len(output_realworld_stra4['full output'])):\n",
    "    print(\n",
    "        np.min([len(output) for output in output_realworld_stra4['full output'][i]]),\n",
    "        np.median([len(output) for output in output_realworld_stra4['full output'][i]]),\n",
    "        np.max([len(output) for output in output_realworld_stra4['full output'][i]])\n",
    "        )"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "528280cb",
   "metadata": {},
   "source": [
    "Load all input and output"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 59,
   "id": "8f12540a",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load results from all runs\n",
    "all_real_results = {\n",
    "    4: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]},\n",
    "    5: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]}\n",
    "}\n",
    "\n",
    "for i in range(len(output_realworld_stra4['full output'])):\n",
    "    for strategy, output_dict in zip(\n",
    "        [4, 5],\n",
    "        [output_realworld_stra4, output_realworld_stra5]\n",
    "    ):\n",
    "        res = calc_eval_metrics(output_dict['full output'][i], real_questions['prompt'], real_prompt_groundtruth_dict)\n",
    "        all_real_results[strategy]['ragllm_input'].append(output_dict['input prompt'][i])\n",
    "        all_real_results[strategy]['ragllm_output'].append(output_dict['full output'][i])\n",
    "        all_real_results[strategy]['full'].append(res)\n",
    "        all_real_results[strategy]['partial'].append(res['partial_match_acc'])\n",
    "        all_real_results[strategy]['exact'].append(res['exact_match_acc'])\n",
    "        all_real_results[strategy]['avg_partial'].append(res['avg_partial_match_acc'])\n",
    "        all_real_results[strategy]['avg_exact'].append(res['avg_exact_match_acc'])\n",
    "\n",
    "def make_eval_df(data, prefix):\n",
    "    return pd.DataFrame(data).T.add_prefix(prefix)\n",
    "\n",
    "real_res_stra4_partial_acc_df = make_eval_df(all_real_results[4]['partial'], 'partial_match_acc_')\n",
    "real_res_stra4_exact_acc_df   = make_eval_df(all_real_results[4]['exact'],   'exact_match_acc_')\n",
    "\n",
    "real_res_stra5_partial_acc_df = make_eval_df(all_real_results[5]['partial'], 'partial_match_acc_')\n",
    "real_res_stra5_exact_acc_df   = make_eval_df(all_real_results[5]['exact'],   'exact_match_acc_')\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "e9b8f2bc",
   "metadata": {},
   "source": [
    "Sanity check - if no output was returned, that means the model failed to generate a response due to the max output tokens limit"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 84,
   "id": "db2e7bc0",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "4\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing breast cancer. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Docetaxel + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with docetaxel for treatment of patients with HER-2 positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: For a patient with HER2+ breast cancer after neoadjvuant chemotherapy + trastuzumab then surgery, if residual disease at time of surgery, what treatment options are approved afterwards?\n",
      "     \n",
      "    \n",
      "17\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a peritoneal cancer patient has a somatic variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a germline variant in gene BRCA2, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).', 'If a pancreatic adenocarcinoma patient has a germline variant in gene BRCA2, and is metastatic, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) has granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regime. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a peritoneal cancer patient has a somatic variant in gene BRCA1, and is primary, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for approved olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA2, and is her2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval to olaparib for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is hrd-positive advanced, one recommended treatment would be Bevacizumab + Olaparib. The U.S. Food and Drug Administration expanded the indication of olaparib to include its combination with bevacizumab for first-line maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Margetuximab-cmkb + Chemotherapy. The U.S. Food and Drug Administration (FDA) approved margetuximab-cmkb in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease. (Citation: MacroGenics, Inc. Margenzat (margetuximab-cmkb) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761150s000lbl.pdf. Revised December 2020. Accessed February 2, 2021.).', 'If a epithelial ovarian cancer patient has a somatic variant in gene BRCA2, and is advanced, one recommended treatment would be Olaparib. The U.S. Food and Drug Administration (FDA) granted approval for olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. (Citation: AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf. Revised May 2023. Accessed July 5, 2023.).', 'If a breast cancer patient has a germline variant in gene BRCA1, and is her2-negative locally advanced or metastatic, one recommended treatment would be Talazoparib. The U.S. Food and Drug Administration (FDA) granted approval for talazoparib indicated for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer. (Citation: Pfizer, Inc. Talzenna (talazoparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211651s010lbl.pdf. Revised June 2023. Accessed July 6, 2023.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "     \n",
      "    \n",
      "18\n",
      "\n",
      "    Context information is below.\n",
      "    ---------------------\n",
      "    ['If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Ado-Trastuzumab Emtansine. HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: (1) Received prior therapy for metastatic disease, or (2) Developed disease recurrence during or within six months of completing adjuvant therapy. (Citation: Genentech, Inc. Kadcyla (ado-trastuzumab emtansine) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125427s108lbl.pdf. Revised September 2020. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is advanced unresectable or metastatic, one recommended treatment would be Capecitabine + Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) granted regular approval for tucatinib, a kinase inhibitor indicated in combination with chemotherapy (trastuzumab and capecitabine) for treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or more prior anti-HER2-based regimens in the metastatic setting. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastroesophageal junction adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is locally advanced unresectable or metastatic, one recommended treatment would be Fluoropyrimidine + Trastuzumab + Pembrolizumab + Platinum. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for the first-line treatments of patients with locally advanced unresectable or metastatic HER2-positive gastric adenocarcinoma. In November 2023, the FDA updated this indication to restrict use to patients whose tumors express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test. (Citation: Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125514s148lbl.pdf. Revised November 2023. Accessed December 5, 2023.).', 'If a breast cancer patient has a copy number in gene ERBB2, and is locally advanced, inflammatory, or early stage, one recommended treatment would be Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) approved a new fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for subcutaneous injection in combination with chemotherapy for the following indications: neoadjuvant treatment for patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer; adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence. (Citation: Genentech, Inc. Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf. Revised June 2020. Accessed November 4, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Pertuzumab + Trastuzumab. The U.S. Food and Drug Administration (FDA) granted accelerated approval to pertuzumab for use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease and use in combination with trastuzumab and chemotherapy as: (1) neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. (2) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence (Citation: Genentech, Inc. Perjeta (pertuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf. Revised January 2020. Accessed November 12, 2020.).', 'If a colorectal cancer patient has a copy number in gene ERBB2, and is unresectable or metastatic, one recommended treatment would be Trastuzumab + Tucatinib. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to tucatinib in combination with trastuzumab for the treatment of adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. (Citation: Seagen, Inc. Tukysa (tucatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Revised January 2023. Accessed February 2, 2023.).', 'If a gastic adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastric adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a gastroesophageal junction adenocarcinoma patient has a copy number in gene ERBB2, and is metastatic, one recommended treatment would be Trastuzumab. The U.S. Food and Drug Administration (FDA) granted approval to trastuzumab for use in the treatment of HER2-overexpressing metastatic gastroesophageal junction adenocarcinoma. (Citation: Genentech, Inc. Herceptin (trastuzumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103792s5345lbl.pdf. Revised November 2018. Accessed November 12, 2020.).', 'If a breast cancer patient has a copy number in gene ERBB2, one recommended treatment would be Lapatinib + Trastuzumab. Lapatinib is a kinase inhibitor indicated in combination with: (1) capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy including an anthracycline, a taxane, and trastuzumab. Limitations of Use: Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib in combination with capecitabine. (2) letrozole for the treatment of postmenopausal women with hormone receptorpositive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. (Citation: Novartis Pharmaceuticals Corporation. Tykerb (lapatinib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022059s024lbl.pdf. Revised December 2018. Accessed November 12, 2020.).']\n",
      "    ---------------------\n",
      "    \n",
      "    If no FDA-approved drugs are found, respond: \"There are no FDA-approved drugs for the provided context.\"\n",
      "    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema. \n",
      "    {\n",
      "        \"Treatment 1\": {\n",
      "            \"Disease Name\": ,\n",
      "            \"Disease Phase or Condition\": ,\n",
      "            \"Drug Name\": ,\n",
      "            \"Prior Treatment or Resistance Status\": ,\n",
      "            \"Genomic Features\": \n",
      "            \"FDA-approval status\":\n",
      "            \"Link to FDA-approved Label\":\n",
      "            }\n",
      "    }\n",
      "    Query: I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n",
      "     \n",
      "    \n"
     ]
    }
   ],
   "source": [
    "stra=4\n",
    "for i,e in enumerate(all_real_results[stra]['ragllm_output'][0]):\n",
    "    if len(e) == 0:\n",
    "        print(i)\n",
    "        print(all_real_results[stra]['ragllm_input'][0][i])\n"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "cd38f683",
   "metadata": {},
   "source": [
    "Strategy 4 - without providing a json schema in the input prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 70,
   "id": "5a006644",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0.7142857142857143, 0.7142857142857143, 0.7619047619047619, 0.7619047619047619, 0.7619047619047619] 0.7428571428571429\n",
      "[0.7619047619047619, 0.8095238095238095, 0.8571428571428571, 0.9047619047619048, 0.7619047619047619] 0.819047619047619\n"
     ]
    }
   ],
   "source": [
    "stra=4\n",
    "print(all_real_results[stra]['avg_exact'], np.mean(all_real_results[stra]['avg_exact']))\n",
    "print(all_real_results[stra]['avg_partial'], np.mean(all_real_results[stra]['avg_partial']))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "ad352710",
   "metadata": {},
   "source": [
    "Strategy 5 - providing a json schema in the input prompt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 71,
   "id": "b9da0a1f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[0.6190476190476191, 0.7142857142857143, 0.7142857142857143, 0.7142857142857143, 0.7619047619047619] 0.7047619047619048\n",
      "[0.8095238095238095, 0.8571428571428571, 0.8095238095238095, 0.7619047619047619, 0.7619047619047619] 0.8\n"
     ]
    }
   ],
   "source": [
    "stra=5\n",
    "print(all_real_results[stra]['avg_exact'], np.mean(all_real_results[stra]['avg_exact']))\n",
    "print(all_real_results[stra]['avg_partial'], np.mean(all_real_results[stra]['avg_partial']))"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "473f956d",
   "metadata": {},
   "source": [
    "### Evaluate GPT4o output "
   ]
  },
  {
   "cell_type": "markdown",
   "id": "3a247b91",
   "metadata": {},
   "source": [
    "#### Real-world"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 93,
   "id": "c8e830b3",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_questions=pd.read_csv(os.path.join(root_dir, 'data/real_world_queries.csv'), index_col=0)\n",
    "real_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/real_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 97,
   "id": "5fa5c2f3",
   "metadata": {},
   "outputs": [],
   "source": [
    "real_rag_res_dict_4 = load_object(filename=os.path.join(root_dir, 'output/RAG_res_gpt4o/realworld/RAGstra4n5temp0.0_res_dict.pkl'))\n",
    "real_rag_res_dict_5 = load_object(filename=os.path.join(root_dir, 'output/RAG_res_gpt4o/realworld/RAGstra5n5temp0.0_res_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 99,
   "id": "803ca0ae",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load results from all runs\n",
    "all_real_results = {\n",
    "    4: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]},\n",
    "    5: {'ragllm_input':[],'ragllm_output':[],'full':[], 'partial':[], 'exact':[], 'avg_partial':[], 'avg_exact':[]}\n",
    "}\n",
    "\n",
    "for i in range(len(real_rag_res_dict_4['full output'])):\n",
    "    for strategy, output_dict in zip(\n",
    "        [4, 5],\n",
    "        [real_rag_res_dict_4, real_rag_res_dict_5]\n",
    "    ):\n",
    "        res = calc_eval_metrics(output_dict['full output'][i], real_questions['prompt'], real_prompt_groundtruth_dict)\n",
    "        all_real_results[strategy]['ragllm_input'].append(output_dict['input prompt'][i])\n",
    "        all_real_results[strategy]['ragllm_output'].append(output_dict['full output'][i])\n",
    "        all_real_results[strategy]['full'].append(res)\n",
    "        all_real_results[strategy]['partial'].append(res['partial_match_acc'])\n",
    "        all_real_results[strategy]['exact'].append(res['exact_match_acc'])\n",
    "        all_real_results[strategy]['avg_partial'].append(res['avg_partial_match_acc'])\n",
    "        all_real_results[strategy]['avg_exact'].append(res['avg_exact_match_acc'])\n",
    "\n",
    "def make_eval_df(data, prefix):\n",
    "    return pd.DataFrame(data).T.add_prefix(prefix)\n",
    "\n",
    "real_res_stra4_partial_acc_df = make_eval_df(all_real_results[4]['partial'], 'partial_match_acc_')\n",
    "real_res_stra4_exact_acc_df   = make_eval_df(all_real_results[4]['exact'],   'exact_match_acc_')\n",
    "\n",
    "real_res_stra5_partial_acc_df = make_eval_df(all_real_results[5]['partial'], 'partial_match_acc_')\n",
    "real_res_stra5_exact_acc_df   = make_eval_df(all_real_results[5]['exact'],   'exact_match_acc_')\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 126,
   "id": "16886c2f",
   "metadata": {},
   "outputs": [],
   "source": [
    "import tiktoken\n",
    "encoding = tiktoken.encoding_for_model(\"gpt-4o\")  # or \"gpt-4\", \"gpt-3.5-turbo\", etc.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 131,
   "id": "218d38fa",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 0.5714285714285714\n",
      "1 0.5714285714285714\n",
      "2 0.6666666666666666\n",
      "3 0.6190476190476191\n",
      "4 0.5238095238095238\n"
     ]
    }
   ],
   "source": [
    "acc_type='partial'\n",
    "stra=4\n",
    "for n in range(len(all_real_results[stra][acc_type])):\n",
    "    print(n, all_real_results[stra][f'avg_{acc_type}'][n])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "2fe9c7f9",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "0 0.8095238095238095\n",
      "3\n",
      "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n",
      "[{'olaparib'}, {'olaparib', 'abiraterone', 'prednisone'}, {'talazoparib', 'enzalutamide'}, {'niraparib', 'abiraterone acetate'}, {'rucaparib'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "412\n",
      "17\n",
      "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "[{'talazoparib'}, {'fulvestrant', 'capivasertib'}, {'olaparib'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "18\n",
      "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n",
      "[{'ado-trastuzumab emtansine'}, {'capecitabine', 'trastuzumab', 'tucatinib'}, {'hyaluronidase-zzxf', 'trastuzumab', 'chemotherapy', 'pertuzumab'}, {'lapatinib'}, {'margetuximab-cmkb', 'chemotherapy'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'pertuzumab', 'trastuzumab'}, {'trastuzumab'}, {'pertuzumab', 'docetaxel', 'trastuzumab', 'hyaluronidase-zzxf'}, {'pertuzumab', 'trastuzumab', 'docetaxel'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "307\n",
      "19\n",
      "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n",
      "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "1 0.8095238095238095\n",
      "3\n",
      "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n",
      "[{'olaparib'}, {'olaparib', 'abiraterone', 'prednisone'}, {'talazoparib', 'enzalutamide'}, {'niraparib', 'abiraterone acetate'}, {'rucaparib'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "412\n",
      "17\n",
      "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "[{'talazoparib'}, {'fulvestrant', 'capivasertib'}, {'olaparib'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "18\n",
      "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n",
      "[{'ado-trastuzumab emtansine'}, {'capecitabine', 'trastuzumab', 'tucatinib'}, {'hyaluronidase-zzxf', 'trastuzumab', 'chemotherapy', 'pertuzumab'}, {'lapatinib'}, {'margetuximab-cmkb', 'chemotherapy'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'pertuzumab', 'trastuzumab'}, {'trastuzumab'}, {'pertuzumab', 'docetaxel', 'trastuzumab', 'hyaluronidase-zzxf'}, {'pertuzumab', 'trastuzumab', 'docetaxel'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "307\n",
      "19\n",
      "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n",
      "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "2 0.8095238095238095\n",
      "3\n",
      "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n",
      "[{'olaparib'}, {'olaparib', 'abiraterone', 'prednisone'}, {'talazoparib', 'enzalutamide'}, {'niraparib', 'abiraterone acetate'}, {'rucaparib'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant\",\n",
      "        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (somatic or germline)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "412\n",
      "17\n",
      "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "[{'talazoparib'}, {'fulvestrant', 'capivasertib'}, {'olaparib'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "18\n",
      "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n",
      "[{'ado-trastuzumab emtansine'}, {'capecitabine', 'trastuzumab', 'tucatinib'}, {'hyaluronidase-zzxf', 'trastuzumab', 'chemotherapy', 'pertuzumab'}, {'lapatinib'}, {'margetuximab-cmkb', 'chemotherapy'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'pertuzumab', 'trastuzumab'}, {'trastuzumab'}, {'pertuzumab', 'docetaxel', 'trastuzumab', 'hyaluronidase-zzxf'}, {'pertuzumab', 'trastuzumab', 'docetaxel'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "152\n",
      "19\n",
      "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n",
      "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "3 0.8095238095238095\n",
      "3\n",
      "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n",
      "[{'olaparib'}, {'olaparib', 'abiraterone', 'prednisone'}, {'talazoparib', 'enzalutamide'}, {'niraparib', 'abiraterone acetate'}, {'rucaparib'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "436\n",
      "17\n",
      "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "[{'talazoparib'}, {'fulvestrant', 'capivasertib'}, {'olaparib'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "18\n",
      "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n",
      "[{'ado-trastuzumab emtansine'}, {'capecitabine', 'trastuzumab', 'tucatinib'}, {'hyaluronidase-zzxf', 'trastuzumab', 'chemotherapy', 'pertuzumab'}, {'lapatinib'}, {'margetuximab-cmkb', 'chemotherapy'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'pertuzumab', 'trastuzumab'}, {'trastuzumab'}, {'pertuzumab', 'docetaxel', 'trastuzumab', 'hyaluronidase-zzxf'}, {'pertuzumab', 'trastuzumab', 'docetaxel'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Chemotherapy + Hyaluronidase-zzxf + Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761170s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "307\n",
      "19\n",
      "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n",
      "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "4 0.8095238095238095\n",
      "3\n",
      "For a patient with cancer metastatic prostate cancer, advanced stage (most often stage IV, but some stage III or earlier potentially) and with BRCA2 mutation, what drugs approved?\n",
      "[{'olaparib'}, {'olaparib', 'abiraterone', 'prednisone'}, {'talazoparib', 'enzalutamide'}, {'niraparib', 'abiraterone acetate'}, {'rucaparib'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "        \"Drug Name\": \"Abiraterone + Prednisone + Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 2\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "        \"Drug Name\": \"Olaparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Progressed following prior treatment with enzalutamide or abiraterone\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208558s025lbl.pdf\"\n",
      "    },\n",
      "    \"Treatment 3\": {\n",
      "        \"Disease Name\": \"Metastatic Prostate Cancer\",\n",
      "        \"Disease Phase or Condition\": \"Metastatic Castration-Resistant Prostate Cancer (mCRPC)\",\n",
      "        \"Drug Name\": \"Abiraterone acetate + Niraparib\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Not specified\",\n",
      "        \"Genomic Features\": \"BRCA2 mutation (germline or somatic)\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216793s000lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "436\n",
      "17\n",
      "I have a patient with de novo metastatic HR+ breast cancer with both a somatic AKT mutation and a germline BRCA2 mutation - what are the standard, recommended first- and second-line treatments for this patient?\n",
      "[{'talazoparib'}, {'fulvestrant', 'capivasertib'}, {'olaparib'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n",
      "18\n",
      "I have a patient with an initial diagnosis of cT3N1 HER2+ breast cancer who received neoadjuvant TCHP and had 1cm of residual disease at surgery. What is the recommended adjuvant treatment for this patient and what are the clinical trials that I should consider?\n",
      "[{'ado-trastuzumab emtansine'}, {'capecitabine', 'trastuzumab', 'tucatinib'}, {'hyaluronidase-zzxf', 'trastuzumab', 'chemotherapy', 'pertuzumab'}, {'lapatinib'}, {'margetuximab-cmkb', 'chemotherapy'}, {'neratinib'}, {'capecitabine', 'neratinib'}, {'pertuzumab', 'trastuzumab'}, {'trastuzumab'}, {'pertuzumab', 'docetaxel', 'trastuzumab', 'hyaluronidase-zzxf'}, {'pertuzumab', 'trastuzumab', 'docetaxel'}]\n",
      "{\n",
      "    \"Status\": \"success\",\n",
      "    \"Treatment 1\": {\n",
      "        \"Disease Name\": \"HER2-positive breast cancer\",\n",
      "        \"Disease Phase or Condition\": \"Adjuvant treatment for patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Drug Name\": \"Pertuzumab + Trastuzumab\",\n",
      "        \"Prior Treatment or Resistance Status\": \"Patients with HER2-positive early breast cancer at high risk of recurrence\",\n",
      "        \"Genomic Features\": \"HER2-positive\",\n",
      "        \"FDA-approval status\": \"Approved\",\n",
      "        \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125409s124lbl.pdf\"\n",
      "    }\n",
      "}\n",
      "152\n",
      "19\n",
      "I have a patient with metastatic HR-negative, HER2-low, PD-L1-negative, breast cancer with no germline BRCA mutation.  For second line, is T-DXd or Sacituzumab govitecan preferred?\n",
      "[{'sacituzumab govitecan'}, {'trastuzumab deruxtecan'}]\n",
      "{\n",
      "    \"Status\": \"no_match\",\n",
      "    \"Message\": \"No drugs are FDA-approved for the provided context\"\n",
      "}\n",
      "25\n"
     ]
    }
   ],
   "source": [
    "acc_type='exact'\n",
    "stra=5\n",
    "for n in range(len(all_real_results[stra][acc_type])):\n",
    "    print(n, all_real_results[stra][f'avg_{acc_type}'][n])\n",
    "    for i, e in enumerate(all_real_results[stra][acc_type][n]):\n",
    "        if e == False:\n",
    "            print(i)\n",
    "            print(real_questions['prompt'][i])\n",
    "            print(real_prompt_groundtruth_dict[real_questions['prompt'][i]])\n",
    "            \n",
    "            output = all_real_results[stra]['ragllm_output'][n][i]\n",
    "            num_tokens = len(encoding.encode(output))\n",
    "            print(output)\n",
    "            print(num_tokens)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "71a104eb",
   "metadata": {},
   "source": [
    "#### Structured vs. Unstructured"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 135,
   "id": "26d725a7",
   "metadata": {},
   "outputs": [],
   "source": [
    "moalmanac_data=pd.read_csv(os.path.join(root_dir, 'data/moa_fda_queries_answers.csv'), index_col=0)\n",
    "synthetic_prompt_groundtruth_dict=load_object(os.path.join(root_dir, 'data/synthetic_prompt_groundtruth_dict.pkl'))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 133,
   "id": "84b6f794",
   "metadata": {},
   "outputs": [],
   "source": [
    "# Load RAG-LLM and baseline results\n",
    "rag_unstruc_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/RAG_res_gpt4o/unstructured/RAGstra0n5temp0.0_res_dict.pkl'))\n",
    "rag_struc_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/RAG_res_gpt4o/structured/RAGstra0n5temp0.0_res_dict.pkl'))\n",
    "llm_res_dict_0 = load_object(filename=os.path.join(root_dir, 'output/LLM_res_gpt4o/stra0n1temp0.0_res_dict.pkl'))\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 136,
   "id": "fcb89cb6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Unstructured: 0.7948717948717948, 0.9017094017094017, 0.49424603174603166\n",
      "Structured: 0.9444444444444444, 0.9529914529914529, 0.793091168091168\n"
     ]
    }
   ],
   "source": [
    "# Calculate evaluation metrics for the RAG-LLM output from the first iteration\n",
    "unstruc_results = calc_eval_metrics(rag_unstruc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "struc_results = calc_eval_metrics(rag_struc_res_dict_0['full output'][0], moalmanac_data['prompt'], synthetic_prompt_groundtruth_dict)\n",
    "\n",
    "print(f\"Unstructured: {unstruc_results['avg_exact_match_acc']}, {unstruc_results['avg_partial_match_acc']}, {unstruc_results['avg_precision']}\")\n",
    "print(f\"Structured: {struc_results['avg_exact_match_acc']}, {struc_results['avg_partial_match_acc']}, {struc_results['avg_precision']}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 140,
   "id": "25a81df7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "474\n",
      "1845\n",
      "2462\n",
      "1845\n",
      "1395\n",
      "1853\n",
      "1646\n",
      "1646\n",
      "1646\n",
      "1646\n",
      "1399\n",
      "1399\n",
      "907\n",
      "489\n",
      "1094\n",
      "1094\n",
      "1098\n",
      "1098\n",
      "1094\n",
      "1094\n",
      "443\n",
      "399\n",
      "423\n",
      "824\n",
      "918\n",
      "824\n",
      "918\n",
      "1255\n",
      "900\n",
      "501\n",
      "2077\n",
      "2002\n",
      "1258\n",
      "2077\n",
      "1228\n",
      "864\n",
      "2077\n",
      "1228\n",
      "1258\n",
      "2077\n",
      "421\n",
      "2077\n",
      "955\n",
      "1573\n",
      "954\n",
      "484\n",
      "1501\n",
      "484\n",
      "449\n",
      "1007\n",
      "456\n",
      "1769\n",
      "492\n",
      "1385\n",
      "492\n",
      "449\n",
      "509\n",
      "456\n",
      "955\n",
      "1525\n",
      "464\n",
      "484\n",
      "480\n",
      "484\n",
      "1772\n",
      "492\n",
      "488\n",
      "492\n",
      "501\n",
      "904\n",
      "477\n",
      "904\n",
      "458\n",
      "2256\n",
      "412\n",
      "1720\n",
      "1286\n",
      "1730\n",
      "1510\n",
      "1510\n",
      "527\n",
      "527\n",
      "527\n",
      "527\n",
      "527\n",
      "477\n",
      "622\n",
      "622\n",
      "802\n",
      "623\n",
      "429\n",
      "1269\n",
      "1275\n",
      "451\n",
      "451\n",
      "973\n",
      "429\n",
      "451\n",
      "451\n",
      "451\n",
      "1428\n",
      "1456\n",
      "506\n",
      "506\n",
      "529\n",
      "529\n",
      "1456\n",
      "1070\n",
      "1070\n",
      "929\n",
      "791\n",
      "805\n",
      "962\n",
      "432\n",
      "465\n",
      "1050\n",
      "502\n",
      "906\n",
      "502\n",
      "502\n",
      "436\n",
      "497\n",
      "521\n",
      "450\n",
      "898\n",
      "513\n",
      "474\n",
      "450\n",
      "898\n",
      "465\n",
      "436\n",
      "450\n",
      "898\n",
      "513\n",
      "1440\n",
      "907\n",
      "474\n",
      "450\n",
      "898\n",
      "457\n",
      "450\n",
      "898\n",
      "465\n",
      "1368\n",
      "3708\n",
      "3708\n",
      "3708\n",
      "3708\n",
      "3708\n",
      "3708\n",
      "890\n",
      "923\n",
      "2837\n",
      "482\n",
      "2569\n",
      "2569\n",
      "475\n",
      "542\n",
      "542\n",
      "472\n",
      "536\n",
      "499\n",
      "1090\n",
      "1090\n",
      "1110\n",
      "1090\n",
      "831\n",
      "451\n",
      "416\n",
      "1342\n",
      "504\n",
      "1670\n",
      "1112\n",
      "2650\n",
      "1064\n",
      "1563\n",
      "945\n",
      "547\n",
      "467\n",
      "430\n",
      "1802\n",
      "1802\n",
      "1368\n",
      "1368\n",
      "496\n",
      "496\n",
      "468\n",
      "468\n",
      "900\n",
      "427\n",
      "1772\n",
      "1772\n",
      "904\n",
      "904\n",
      "429\n",
      "428\n",
      "455\n",
      "914\n",
      "906\n",
      "1368\n",
      "1772\n",
      "1368\n",
      "1802\n",
      "445\n",
      "893\n",
      "438\n",
      "454\n",
      "460\n",
      "864\n",
      "564\n",
      "577\n",
      "588\n",
      "590\n",
      "591\n",
      "589\n",
      "2663\n",
      "392\n",
      "399\n",
      "1657\n",
      "1286\n",
      "1721\n",
      "1286\n",
      "1721\n",
      "791\n",
      "785\n",
      "428\n",
      "824\n",
      "1225\n",
      "429\n",
      "2462\n",
      "2462\n",
      "2462\n",
      "513\n",
      "469\n"
     ]
    }
   ],
   "source": [
    "for i, output in enumerate(rag_struc_res_dict_0['full output'][0]):\n",
    "    if len(output) == 0:\n",
    "        print(i)\n",
    "    elif output == None:\n",
    "        print(i)\n",
    "    else: \n",
    "        print(len(output))"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "base",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.10.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
